The life sciences practice at Hogan Lovells International LLP has expertise spanning pharmaceuticals, medical devices, and healthcare regulatory issues, advising leading pharmaceutical clients on contentious and non-contentious matters. Cláudia Mendes Pinto is key to the team, frequently working on EU and global projects, focusing on advanced therapy medicinal products. Helene Boland is also noted. Former head of practice Fabien Roy left the firm post-publication in January 2026.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
- Adverum Biotechnologies
- Balt USA, LLC
- Celgene Corporation
- Dexcom, Inc.
- Establishment Labs
- Synapse Biomedical, Inc.
Work highlights
Advising Adverum, a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, on setting up a GDPR-compliant framework for their upcoming clinical trials in the EU and UK and on future clinical activities in the EU/UK.
Advising Celgene on an ongoing basis with supply chain, manufacturing, and clinical trials regulatory aspects throughout Europe.
Advising clients on the transition of their devices from the Medical Devices Directive to the Medical Devices Regulation.
Lawyers
Leading associates
Leading associates with regular involvement in their team's key work, and recognition from peers or clients as being ones to watch.
Other key lawyers
Claudia Mendes Pinto; Helene Boland